patent.fyi
Applications  /  US 2026/0355233
United States Patent Application Publication

US 2026/0355233 A1

Published
Nov 12, 2026
Filed
May 10, 2025
Earliest date on the face
May 10, 2025
Classification
A61K 33/18
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Shielding for external photons

What ifWhat if a freestanding shield provides protection during external X-ray exposure?
Claim language“Sea Buckthorn Oil”

A lead-lined panel sits between the X-ray source and the subject. Lead thickness is selected for the photon energy range, and a dosimeter on the subject side measures the transmitted dose.

1.1Remote handling increases distance

What ifWhat if a remote manipulator provides protection by increasing the distance between the operator and a sealed radiation source?
Claim language“Sea Buckthorn Oil”

A motorized gripper transfers the sealed source while the operator remains at a separate control station. For a compact source in open geometry, doubling the distance reduces the direct dose rate to approximately one-quarter.

1.2Binding cesium in the gut

What ifWhat if insoluble ferric hexacyanoferrate reduces the retained activity after internal contamination with radioactive cesium?
Claim language“sodium iodate”

Oral capsules release insoluble ferric hexacyanoferrate into the gastrointestinal tract. The solid binds cesium in the gut, interrupts its reabsorption, and increases its elimination in stool.

1.2Stimulation of neutrophil recovery

What ifWhat if an injected granulocyte colony-stimulating factor supports recovery after radiation-induced marrow injury?
Claim language“afforded by phenylbutyrate”

A subcutaneous formulation delivers a recombinant protein that activates receptors on surviving myeloid progenitor cells and promotes neutrophil production. Serial blood counts track the absolute neutrophil count during recovery.

1.3Bedside dispensing under supervision

What ifWhat if a clinician dispenses the components at the bedside from a tray supplied without an instruction insert or digital directions?
Claim language“includes instructions”

The tray holds separately sealed components with identity and lot labels. The clinician selects and releases each component against an individualized order in the patient record.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Staged kit for veterinary response drills

A veterinary referral hospital uses a three-compartment kit in exercises for simulated radiation incidents involving animals. The compartments contain sealed training units and carry labels for protection, mitigation, and recovery. An instructor issues simulated exposure and assessment records, and trainees select the matching compartment and record each handoff.

Component substitution

Electronic instructions on a passive tag

A passive near-field communication tag replaces the printed instruction booklet on the kit lid. The tag stores a link to a versioned instruction file that a handheld reader caches for offline access. The file presents the three stages in order and uses the same identifiers as the compartment labels.

Parameter or scale variation

Modular storage for twelve staged kits

A transport case holds 12 removable trays in a three-by-four rack. Each tray has three lidded compartments arranged in a fixed order for protection, mitigation, and recovery. The tray and its three compartments share a serial number, and a removable card records the issue and return times for that tray.

Combination with existing systems

Kit tracking through pharmacy inventory software

The pharmacy inventory system stores the outer kit as a parent record and the three stage packages as child records. Each package carries a two-dimensional barcode, and its inventory record stores the lot number, expiration date, and storage location. Scanning a stage package at issue updates the parent kit record and places the kit on a replenishment list.

Automated or data-driven variant

Timed drill prompts from event records

A drill application stores a simulated exposure timestamp and three instructor-configured prompt times relative to that timestamp. At each prompt, the application displays the corresponding stage label and requests a scan of the matching training compartment. It logs the scan time and flags a mismatch between the scanned compartment and the scheduled stage.

Temperature logging for staged kit storage

A battery-powered temperature logger clips inside the outer case and records a timestamped reading every five minutes. Inventory software compares the readings with the storage limits recorded for each of the three stage packages. The software lists the affected package identifiers and the duration of each temperature excursion on the kit inspection screen.

Specific version of a part

Oil in soft gelatin capsules

Each soft gelatin capsule contains 500 mg of sea buckthorn oil as a liquid fill. An opaque foil blister encloses each capsule and limits light exposure during storage.

Phenylbutyrate in measured powder sachets

Each foil-laminate sachet contains 1 g of sodium phenylbutyrate powder in a factory-measured fill. The sachet label identifies the salt form and the mass of that salt per unit.

Printed timing card

A folded card contains separate rows for pre-exposure use, early post-exposure use, and follow-up. Each row identifies the corresponding component and provides fields for recording the exposure time and administration time.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2006/0045912 A1
Published
Mar 2, 2006
Filed
Aug 30, 2005
Class
A61K 9/22
Document BUS 2022/0118041 A1
Published
Apr 21, 2022
Filed
Oct 15, 2021
Class
A61K 36/72
Claim 1
Document A
Document B
1.1the radioprotection is afforded by Sea Buckthorn Oil (orally, up to 15 g/day)
A plant-extracted oil oral supplement comprising: a combination of sea buckthorn oil with at least one phytonutrient to reload adipocytes; palmitelaidic acid from sea buckthorn fruit oil and epigallocatechin from sea buckthorn seed oil and/or sea buckthorn pulp oil to improve conversion of calcium ATP-ase to magnesium ATP-ase and facilitate absorption of epigallocatechin (EPCG) into adipocytes; wherein the supplement is administered over about a 3 month cycle at about 2 table
B · US 2022/0118041 A1 · claim 12
1.2wherein the radiomitigation is afforded by sodium iodate (155 mg qs 100 ml water, orally per day), and the radiorecovery is afforded by phenylbutyrate (orally, up to 30 g/day)
A commercial embodiment of this technology is an oral dose powder packet of sodium phenylbutyrate marketed by ForTe Beheer B V (The Netherlands).
A · US 2006/0045912 A1 · ¶ 14
1.3wherein the kit includes instructions and components provide synergistic benefit against radiation exposure.

An empty cell means only that no passage was reproduced there.

Statements in these documents
The invention provides controlled-release pharmaceutical formulations of 4-phenylbutyric acid and its pharmaceutically acceptable salts, solvates, esters and prodrugs for therapeutic use.
A · US 2006/0045912 A1 · ¶ 2
Controlled-release 4-phenylbutyric acid formulations are useful in the treatment of various disorders, including cancer (e.g., prostate cancer) and neurodegenerative diseases (e.g., spinal muscular atrophy, amyotrophic lateral sclerosis).
A · US 2006/0045912 A1 · ¶ 2
A vast majority of health conditions and even diseases are the direct result of specific nutrient shortages that come about from chronic inflammation, toxicity, pathogen utilization, infection, and/or poor dietary habits.
B · US 2022/0118041 A1 · ¶ 2
Benefits may include, but are not limited to, repair of fat pad atrophy in the face and body, the treatment of high cholesterol, the treatment of diabetes, the clearance of allergies, improvements in high blood pressure, the improvement of skin conditions like acne, eczema, psoriasis, seborrheic dermatitis, perioral dermatitis, improvements in astigmatism, and more.
B · US 2022/0118041 A1 · ¶ 6
Cite aspatent.fyi, US 2026/0355233 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355233/, SHA-256 ed42bb0c920b6a9667a6afd3a96dd9c470649c670646efe5723920d973e3ffbe
First published
Permanent addresshttps://patent.fyi/US20260355233/
Content fingerprint (SHA-256)ed42bb0c920b6a9667a6afd3a96dd9c470649c670646efe5723920d973e3ffbe
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi